Summary

Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), commended the results of the collaborative HIV vaccine trial that has been conducted in Thailand over the past six years. The Phase III clinical trial involving more than 16,000 adult volunteers in Thailand has demonstrated that an investigational HIV vaccine regimen was safe and modestly effective in preventing HIV infection.

Analysis

Promising results.  A few details of the study were left out of the article reference, but what is shown (at face value) seems good.

Any advancements in the fight against HIV/AIDS will do wonders for the world.  As some have been saying each day 7500 new people are infected with HIV worldwide on a DAILY BASIS.  and 2million people died of AIDS last year.
Vaccinations will be our only hope of stopping the spread of this virus, it seems like.
The main issue with vaccinations for HIV is that it is a dirty virus and not very good at making identical replications of itself.  Just as with Hepatitis C.
We can only hope.....

This author consults with leading institutions through GLG

Engage this author or other Healthcare experts
 
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.